EVA Pharma Launches Hepatitis B Treatment Tenofinamide® Tablets
Cairo, February 28, 2021 – EVA Pharma announced the launch of Tenofinamide® tablets for the treatment of chronic hepatitis B virus (HBV) infection.
Tenofinamide® tablets have the active pharmaceutical ingredient tenofovir alafenamide 25 mg which reduces the viral load while reducing side effects on kidneys and bones.
“For almost 16 years, we have been continuously providing novel HBV treatments for patients improving the quality of life for thousands of patients, not only in Egypt but also globally in all countries we export to.” said Dr. Amgad Talaat, specialty business unit manager at EVA Pharma.
In 2016 the U.S. Food and Drug Administration has approved the use of the active ingredient tenofovir alafenamide TAF in the treatment of hepatitis B, which is a new substance of the tenofovir ingredient in Tenaviron®, also produced by EVA Pharma, but at a dose 10 times less thus allowing the new formulation to be more effective, liver cells-specific and safe.
Dr. Gamal Esmat, Professor of Hepatology and World Health Organization Advisor said: “Hepatologists and epidemiologists estimate the number of patients with Hepatitis B virus to be 1.4 million patients, some of whom are undiagnosed yet. No curative treatment has been developed yet for hepatitis B, as is the case for hepatitis C, so it is important to spread awareness on the disease to make an early diagnosis and protect those who are not infected.
Therefore, the availability of Tenofenamide® in Egypt is an opportunity for a large number of hepatitis B patients, as the drug reduces the viral load improving the state of the liver with much fewer side effects in comparison to its counterpart treatment. Also, it is an opportunity for hepatitis B patients whose bodies have acquired resistance against other drug classes while the bodies’ resistance against Tenofenamide® is almost zero which is considered the most appropriate option for geriatric patients and those suffering from kidney and bone problems.”